Metanephrine Level, Urine 24 Hrs

Reproductive

Report in 120Hrs

At Home

Fasting Required

Details

Catecholamine metabolites.

₹5,180₹7,400

30% OFF

Metanephrine Level, Urine 24 Hrs - Comprehensive Medical Guide

Why is it done?
- What the test measures: This test measures metanephrine and normetanephrine levels in a 24-hour urine collection. These are breakdown products of the catecholamine hormones (epinephrine and norepinephrine) produced by the adrenal glands and sympathetic nervous system.
- Primary indications for testing: Detection and diagnosis of pheochromocytoma (catecholamine-secreting tumor); Evaluation of persistent or resistant hypertension; Investigation of episodic symptoms including sudden headaches, profuse sweating, and palpitations; Screening for multiple endocrine neoplasia (MEN) syndromes; Monitoring of known pheochromocytoma; Assessment of unexplained anxiety or panic attacks with physical symptoms.
- Typical timing and circumstances: Ordered during initial diagnostic evaluation for suspected pheochromocytoma; Performed when patients present with classic triad of sudden severe headache, profuse sweating, and palpitations; Used in follow-up monitoring after pheochromocytoma treatment; Part of routine screening in patients with genetic syndromes predisposing to catecholamine-secreting tumors.
Normal Range
- Reference values: Metanephrine: 24-96 mcg/24 hrs; Normetanephrine: 75-390 mcg/24 hrs; Total metanephrines: <400 mcg/24 hrs or <2.2 nmol/day (values may vary by laboratory)
- Units of measurement: micrograms per 24 hours (mcg/24 hrs), nanomoles per day (nmol/day), or picomoles per kilogram per day (pmol/kg/day) depending on laboratory standards
- Interpreting results: Normal (negative): Metanephrine and normetanephrine levels within reference range; essentially rules out pheochromocytoma with high sensitivity; Elevated (positive): Values exceeding reference range suggest possible pheochromocytoma or other catecholamine-producing condition; Borderline/Gray zone: Mildly elevated values may require repeat testing or additional diagnostic evaluation; Multiple increases suggest higher likelihood of pathology.
- What normal vs. abnormal means: Normal results indicate appropriate catecholamine metabolism and effective adrenal function; highly sensitive test making negative results reliable for excluding pheochromocytoma; Abnormal results indicate excessive catecholamine production requiring further diagnostic imaging and clinical correlation.
Interpretation
- Interpreting different result values: Results within normal range with clinical suspicion: Pheochromocytoma unlikely but does not completely exclude; Consider repeat testing during or shortly after acute symptoms; Results 1-4 times upper limit of normal: Warrants further investigation with imaging studies (CT, MRI); Results >4 times upper limit: Strong evidence of pheochromocytoma; Confirm with imaging and assess for metastases.
- What different results indicate: Elevated metanephrine only: Suggests adrenal pheochromocytoma; Elevated normetanephrine only: Suggests extra-adrenal pheochromocytoma or paraganglioma; Both elevated: Indicates catecholamine excess, primary versus secondary etiology must be determined; Very high levels: Associated with malignant pheochromocytoma.
- Factors affecting results: Medications: Decongestants, sympathomimetics, antidepressants, stimulants, and some blood pressure medications can elevate results; Physical stress and exercise during collection period; Caffeine and nicotine consumption; Sleep deprivation; Acute illness or infection; Improper specimen collection or storage; Certain foods containing tyramine; Anesthesia exposure; Anxiety and emotional stress.
- Clinical significance: This is the screening test of choice for pheochromocytoma with superior sensitivity and specificity; Test is most reliable when patient avoids interfering substances; Elevated results necessitate confirmatory imaging before definitive diagnosis; Results guide surgical planning and long-term management decisions; Negative results in symptomatic patients may suggest secondary hypertension or other etiologies.
Associated Organs
- Primary organ systems involved: Adrenal glands (primary site of catecholamine production); Sympathetic nervous system (scattered chromaffin cells); Kidneys (through which metanephrines are excreted); Cardiovascular system (affected by excessive catecholamine stimulation); Nervous system (affected by hormone action).
- Conditions associated with abnormal results: Pheochromocytoma (benign catecholamine-secreting tumor); Malignant pheochromocytoma with metastases; Paraganglioma (extra-adrenal pheochromocytoma); Neurofibromatosis type 1 (NF1); Multiple endocrine neoplasia type 2A and 2B (MEN2); Familial paraganglioma syndromes; Secondary hypertension with catecholamine excess.
- Diseases this test helps diagnose or monitor: Pheochromocytoma diagnosis and localization; Recurrent pheochromocytoma after surgical treatment; Malignant pheochromocytoma with metastatic disease; Hereditary catecholamine-producing tumor syndromes; Resistant hypertension with suspicious symptoms; Paroxysmal hypertension of unclear etiology.
- Potential complications of abnormal results: Hypertensive crisis and stroke from uncontrolled catecholamine release; Myocardial infarction from cardiac ischemia; Arrhythmias and sudden cardiac death; Pulmonary edema from acute left ventricular dysfunction; Acute kidney injury from severe hypertension; Diabetic ketoacidosis or hyperglycemic crisis; Seizures or neurological complications; Death during surgical removal if inadequately prepared; Metastatic disease if pheochromocytoma is malignant.
Follow-up Tests
- Additional tests based on abnormal results: Plasma free metanephrine test (confirmatory); Abdominal CT scan (localize tumor); Abdominal MRI (if CT inconclusive or contraindicated); Chest CT (assess for thoracic paraganglioma); MIBG scintigraphy (functional imaging); PET scan (detect metastases); Pituitary MRI (if MEN syndrome suspected).
- Further investigations needed: Genetic testing for hereditary tumor syndromes (NF1, MEN2, SDH mutations); Ophthalmologic evaluation for neurofibromas (NF1 screening); Thyroid ultrasound or scan (MEN2 screening); Complete metabolic panel and glucose assessment; 24-hour urine cortisol if Cushing syndrome suspected; ECG and echocardiography for cardiac assessment.
- Monitoring frequency for known pheochromocytoma: Post-surgical: Every 6-12 months for 5 years, then annually; Long-term follow-up: Indefinite monitoring given recurrence risk; Malignant disease: More frequent monitoring (every 3-6 months); Genetic syndrome carriers: Annual screening; After treatment completion: Surveillance for recurrence with periodic urine metanephrines.
- Related complementary tests: Plasma catecholamines (epinephrine and norepinephrine levels); Chromogranin A (general neuroendocrine marker); Vanillylmandelic acid (VMA) in 24-hour urine (alternative test); Blood pressure monitoring (assess hypertensive control); Blood glucose (assess for hyperglycemia); Electrolytes (hypokalemia assessment); Cardiac enzymes (assess myocardial stress).
Fasting Required?
- Fasting requirement: NO - Fasting is not required for this test
- Medications to avoid before collection: Decongestants containing phenylephrine or pseudoephedrine (48 hours before); Cold and allergy medications with sympathomimetics; Stimulants including amphetamines and methylphenidate; Some antidepressants (particularly tricyclics and SNRIs) - consult with physician; Nasal sprays with vasoconstrictors; Over-the-counter appetite suppressants; Bronchodilators (non-essential use); MAO inhibitors - critical to avoid.
- Dietary restrictions during collection: Avoid foods high in tyramine (aged cheeses, cured meats, fermented foods, soy sauce); Limit or eliminate caffeine (coffee, tea, cola, chocolate); No nicotine or tobacco products during collection period; Avoid alcoholic beverages; No stimulant-containing products; Minimize licorice consumption.
- General patient preparation requirements: Obtain special 24-hour urine collection container (usually with preservative) from laboratory; Urinate normally in morning, discard first specimen, start collection from second void; Collect all urine over next 24 hours into provided container; Keep container refrigerated or on ice during collection; Write exact start and end times on container; Avoid extreme physical stress and exercise during collection; Remain calm and minimize anxiety during collection period; Keep container away from direct sunlight; Notify healthcare provider of any acute illness during collection; Return specimen to laboratory promptly after collection; Clarify timing - some recommend immediate 24-hour collection period, others prefer collection during period without acute symptoms.
- Special considerations: Patient should be in seated position for at least 30 minutes before collection if doing baseline test; If collecting during symptomatic episode, notify laboratory; Women should avoid collection during menstruation if possible (may increase catecholamine levels); Inform laboratory of any acute stressors or illness during collection; Repeat testing may be needed if preparation inadequate; Coordinate timing with physician to minimize test-interfering factors; Document all interfering substances and medications on requisition form.

How our test process works!